Teva Pharmaceutical Industries' active pharmaceutical ingredients
(API) business is on track to become a $1 billion enterprise this
year, although growth in the first quarter of this year was almost
entirely from in-house sales,...
Teva Hungary, a subsidiary of number two generic company Teva
Pharmaceuticals, is to build a $100 million (€75m) factory for the
production of active pharmaceutical ingredients (APIs) in
Sajobabony, Hungary.
The consolidation of the generic drugs industry continues, with
Novartis' unit Sandoz merging with two companies that will bring it
back into the number one position in the sector.
Israeli drug and active pharmaceutical ingredients (API) company
Teva has reported a sharp increase in sales in 2004, helped in part
by last year's $3.4bn (€2.6bn) acquisition of Sicor.
Isael's Teva Pharmaceutical Industries slipped into a loss in the
first quarter of 2004, as the cost of the acquisition of US
generics and active pharmaceutical ingredient (API) firm Sicor took
its toll, but for the first time...
Israel's Teva has moved a step closer to consolidating its position
as the world's biggest generics manufacturer with the $3.4 billion
(€2.7bn) acquisition of US-based SICOR, which makes active
pharmaceutical ingredients...
Israel's Teva plans to buy Sicor in a €2.9bn deal that will create
a powerhouse in generic pharmaceuticals and active pharmaceutical
ingredient manufacturing.
